AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Novonesis AS

Transaction in Own Shares Mar 2, 2015

3377_dirs_2015-03-02_72e3b802-7721-4c56-9d83-ad7f03fdcf08.pdf

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

March 2, 2015

As of February 27, Novozymes has purchased an accumulated 741,000 shares with a transaction value of DKK 230.1 million under the stock buyback program Novozymes announced in Company announcement No. 6, 2015 and initiated February 2, 2015. Under the program, Novozymes will buy back B shares worth up to DKK 2 billion in total during 2015.

The following transactions have been made under the program in accordance with the provisions of European Commission Regulation (EC) No. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour Regulation:

Number of shares Average purchase price Transaction value, DKK
Accumulated, last announcement 604,000 185,657,824
23 February 2015 29,000 327.86 9,507,996
24 February 2015 25,000 327.03 8,175,793
25 February 2015 25,000 323.38 8,084,521
26 February 2015 30,000 322.59 9,677,719
27 February 2015 28,000 322.05 9,017,414
Accumulated under the program 741,000 230,121,267

In addition, transactions necessitated by Novozymes' previously established incentive programs have resulted in a net sale by Novozymes of 40,445 B shares in the period from February 23 to February 27, 2015. The share transactions related to the incentive programs were not part of the Safe Harbour stock buyback program.

Following the transactions stated above, Novozymes owns a total of 11,432,954 treasury shares, corresponding to 3.6% of the stock capital. The total number of shares in the company is 319,700,000, including treasury shares.

Contact information

Investor Relations:
Thomas Bomhoff (DK) +45 3077 1226 [email protected]
Klaus Sindahl (DK) +45 5363 0134 [email protected]
Martin Riise (USA) +1 919 649 2565 [email protected]

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.

Krogshoejvej 36 2880 Bagsvaerd Denmark

Telephone: +45 4446 0000 Email: [email protected] Internet: www.novozymes.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.